Legislative Proposal
|
Aboriginal Health; Access to Information Act; Data Protection; Drug Product Review & Approval System; Economic Diversification-Prairies; Food and Drugs Act (Cross Border Trade [CBT], Drug Export Restrictions, Regulatory Policies); Health Protection Act (Legislative Renewal); Patent Act; Personal Information Protection and Electronic Documents Act;Pre-Budget Consultations; Privacy Act; Progressive Licensing Framework
|
Regulation
|
Access to Information Act & Regs; Cdn Environmental Protection Act (New Substance Notification);Federal Accountability Act Regs; Food & Drugs Act Regulations (Drug Review & Approval Systems & Regs, data protection, Direct-to-Consumer Advertising Regs, New Substance Notification, Clinical Registry and Disclosure Regs, Clinical Trials Regulatory Framework,GMP & Establishment Licensing); Jean Chrétien Pledge to Africa Act Regs; Lobbyist Registration Act Regs;Patent Act (PM[NOC] Linkage Regs); Patented Medicines Prices Review Board Regs & Discussion Document; Veterinary Biologics Regulatory Review [CFIA] (New Product Licensing Guidelines, Licensing of USDA Approved Products for Companion Aanimals, Conditional Licensing Guidelines)
|
Bill or Resolution
|
C-2 (Federal Accountability Act);C-420 (Removal of FDA Schedule A);Competition Act Amendments
|
Grant, Contribution or Other Financial Benefit
|
CONTINUATION OF "POLICIES OR PROGRAM" SECTION ABOVE:Pharmacogenomics/Biomarkers;PMPRB (policies/guidelines/appointments);Proposed Clinical Trials Registry-Disclosure;Rx to OTC Switch Policies;SMART Regs;Drug-Vaccine Review & Approval Systems (Health & CFIA);tobacco policy =============================================================================================================================================DESCRIPTION OF THE GRANT, CONTRIBUTION OR OTHER FINANCIAL BENEFIT: CIHR grants
|
Policy or Program
|
Pharmacovigilance:AE Reporting; Drug Safety;Cancer Ctrl; CIHR/other health research funding pgrms;Clinical Assessment of Abuse Liability for Drugs w/ CNS Activity-Draft Guidance;Clinical Eval of QT/QTc Interval Prolongation & Proarrhythmic Potential for Non-Antarrythmic Drugs-Adoption of ICH Guidelines;Cost Recovery & Performance;Trade;Drugs Review & Approval Systems;Drug Supply Network;Fed Reimbursement Drug Prgms;FPT Initiatives (CDR, COMPUS, NPDUIS);FDA Regs-Associated Policies & Guidelines (GMP & Establishment Licensing/Probationary/Progressive Licensing Framework);Drug Product Licensing; Memo of Understanding-USFDA;Pharma & Biological Policies & Guidelines; Therapeutic Access;HPFB External Charging Program; HIV/AIDS;Intellectual Property;Innovation;Mgmt of Submissions;Mental Health;Minor Use Minor Species Draft Guidelines;Economic Development;Nat'l Pharma Strategy;
|